Latest News, Press Releases & Events

Cystic Fibrosis News Today: Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing

In Interview, Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing A preclinical study using animal models of cystic fibrosis (CF) showed that SPX-101, a treatment being developed by Spyryx Biosciences, effectively cleared lung mucus in the animals, regardless of the presence of genetic mutations that promote the development of the disease. […]

Continue Reading

Spyryx Biosciences Emerging Company Profile in BioCentury

EMERGING COMPANY PROFILE GOING SPLUNCING BY EMILY CUKIER-MEISNER, SENIOR WRITER Spyryx Biosciences Inc. is developing inhaled peptides for cystic fibrosis that inhibit the sodium channel responsible for regulating fluid volume in the lungs. The peptides could offer a pan-genotypic treatment that is more efficacious than therapies targeting CFTR. CF is caused by defects in the […]

Continue Reading